Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Colorcon
Baxter
Moodys

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,025,635

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,025,635 protect, and when does it expire?

Patent 8,025,635 protects SINUVA and is included in one NDA.

This patent has fourteen patent family members in ten countries.

Summary for Patent: 8,025,635
Title:Device and methods for treating paranasal sinus conditions
Abstract: Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.
Inventor(s): Eaton; Donald J. (Woodside, CA), Tice; Thomas R. (Indian Springs, AL), Downie; David B. (Cupertino, CA), Arensdorf; Patrick A. (Palo Alto, CA), Brenneman; Rodney (San Juan Capistrano, CA), Biggs; Danielle L. (Hoover, AL)
Assignee: Intersect ENT, Inc. (Palo Alto, CA)
Application Number:11/398,342
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 8,025,635

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No   Start Trial   Start Trial Y TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,025,635

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006231506   Start Trial
Canada 2603081   Start Trial
China 101189016   Start Trial
European Patent Office 1871383   Start Trial
European Patent Office 2298317   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKesson
Baxter
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.